Janjigian, Y. Y., Park, B. J., Zakowski, M. F., Ladanyi, M., Pao, W., D’Angelo, S. P., . . . Azzoli, C. G. (2011). Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations.
Citação norma ChicagoJanjigian, Yelena Y., et al. Impact On Disease-free Survival of Adjuvant Erlotinib or Gefitinib in Patients With Resected Lung Adenocarcinomas That Harbor Epidermal Growth Factor Receptor (EGFR) Mutations. 2011.
Citação norma MLAJanjigian, Yelena Y., et al. Impact On Disease-free Survival of Adjuvant Erlotinib or Gefitinib in Patients With Resected Lung Adenocarcinomas That Harbor Epidermal Growth Factor Receptor (EGFR) Mutations. 2011.